View:
Download DOC
Download PDF
Download XLS

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 5, 2018

 

IMPRIMIS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-35814   45-0567010

(State or other jurisdiction

of incorporation)

   (Commission
File Number)		   (IRS Employer
Identification No.)

 

12264 El Camino Real, Suite 350    
San Diego, CA   92130
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (858) 704-4040

 

N/A

 

(Former name or former address if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 
 

 

Item 1.02   Termination of a Material Definitive Agreement.

 

On November 5, 2018, Imprimis Pharmaceuticals, Inc. (the “Company”) provided notice of termination to Cantor Fitzgerald & Co. (“Cantor”) of the Controlled Equity OfferingSM Sales Agreement, dated November 27, 2015 (the “Sales Agreement”), by and between the Company and Cantor. The termination will become effective on November 15, 2018, following a ten-day notice period pursuant to Section 13(b) of the Sales Agreement.

 

The Company is terminating the Sales Agreement because it estimates that cash flow provided by operations will be sufficient to fund its operating expenses, capital expenditures and working capital requirements for at least the next twelve (12) months, and it will not need to sell its common stock through the Sales Agreement to fund its planned level of operations.

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  IMPRIMIS PHARMACEUTICALS, INC.
                               
Dated: November 6, 2018 By: /s/ Andrew R. Boll
  Name: Andrew R. Boll
  Title: Chief Financial Officer